• Citer

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

par Cristofanilli, Massimo;Pierga, Jean Yves Ves J.Y.;Reuben, James;Rademaker, Alfred;Davis, Andrew ;Peeters, D;Fehm, Tanja;Nolé, Franco;Gisbert-Criado, Rafael;Mavroudis, D;Grisanti, Salvatore;Giuliano, Mario;Garcia-Saenz, Jose A;Stebbing, Justin;Caldas, Carlos;Gazzaniga, Paola;Manso, Luis;Zamarchi, Rita;de Lascoiti, Angela Fernandez;De Mattos-Arruda, Leticia;Ignatiadis, Michail ;Cabel, Luc;Van Laere, S;Meier-Stiegen, Franziska;Sandri, Maria Teresa;Vidal, J.L.Martínez;Politaki, Eleni;Consoli, Francesca;Generali, Daniele;Cappelletti, M L;Diaz-Rubio, Eduardo;Krell, Jonathan;Dawson, Sarah Jane;Raimondi, Cristina;Rutten, Annemie;Janni, Wolfgang;Munzone, Elisabetta;Carañana, Vicente;Agelaki, Sofia;Almici, Camillo;Dirix, Luc Y;Solomayer, Erich-Franz;Zorzino, Laura;Darrigues, Lauren;Reis-Filho, Jorge Sergio;Gerratana, Lorenzo;Michiels, Stefan ;Bidard, François-Clément;Pantel, Klaus
Référence Critical reviews in oncology/hematology, 134, page (39-45)
Publication Publié, 2019-02-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.